Logo

ANGO

AngioDynamics, Inc.

ANGO

AngioDynamics, Inc. • NASDAQ
$12.40 ▲ 0.81% (+0.10)
Market Cap $508.16 M
52w High $13.50
52w Low $6.91
Dividend Yield 0%
P/E -15.9
Volume 272.30K
Outstanding Shares 40.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $75.711M ▼ $52.513M ▲ $-10.903M ▼ -14.401% ▼ $-0.26 ▼ $-4.814M ▼
Q4-2025 $80.158M ▲ $48.006M ▼ $-6.05M ▼ -7.548% ▼ $-0.15 ▼ $2.2M ▲
Q3-2025 $72.004M ▼ $48.831M ▼ $-4.407M ▲ -6.12% ▲ $-0.11 ▲ $-329K ▼
Q2-2025 $72.845M ▲ $51M ▲ $-10.738M ▲ -14.741% ▲ $-0.26 ▲ $1.793M ▲
Q1-2025 $67.491M $49.822M $-12.798M -18.963% $-0.31 $-1.926M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $38.762M ▼ $265.642M ▼ $86.787M ▼ $178.855M ▼
Q4-2025 $55.893M ▲ $280.144M ▼ $97.174M ▼ $182.97M ▼
Q3-2025 $44.76M ▼ $285.415M ▼ $99.545M ▼ $185.87M ▼
Q2-2025 $54.089M ▼ $291.55M ▼ $104.782M ▲ $186.768M ▼
Q1-2025 $55.005M $293.628M $97.046M $196.582M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-10.903M ▼ $-15.914M ▼ $-1.551M ▲ $143K ▲ $-17.131M ▼ $-16.645M ▼
Q4-2025 $-6.05M ▼ $18.811M ▲ $-2.623M ▲ $-5.77M ▼ $11.133M ▲ $18.034M ▲
Q3-2025 $-4.407M ▲ $-13.159M ▼ $-3.189M ▼ $7.147M ▲ $-9.329M ▼ $-14.957M ▼
Q2-2025 $-10.738M ▲ $2.473M ▲ $-1.961M ▲ $-1.123M ▼ $-916K ▲ $1.676M ▲
Q1-2025 $-12.798M $-18.253M $-2.405M $-509K $-21.051M $-19.345M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Med Device
Med Device
 $40.00M ▲$40.00M ▲$40.00M ▲$40.00M ▲
Med Tech
Med Tech
 $30.00M ▲$30.00M ▲$30.00M ▲$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement AngioDynamics shows fairly steady sales over the past several years, but the business is not yet profitable. Gross margins look reasonable for a medical device company, suggesting the products themselves are priced and costed sensibly. The main issue sits below the gross profit line: operating expenses, including R&D and selling costs, consistently push results into the red. The most recent year looks better than the prior year, which had an unusually large loss, but earnings are still negative. Overall, the income statement tells a story of a company investing heavily in its growth platforms while still searching for scale and efficiency to move into sustainable profitability.

Balance Sheet

Balance Sheet The balance sheet has become smaller over time, with total assets and equity shrinking, which often reflects divestitures, write-downs, or a tighter strategic focus. Debt has been paid down to essentially zero, which reduces financial risk and interest burden. Cash levels are modest but improved compared with a few years ago, so the company has some financial flexibility but not a large cushion. In short, AngioDynamics now runs a leaner, less leveraged balance sheet, but on a smaller asset base that needs to generate better returns to justify past investments.

Cash Flow

Cash Flow Cash generation remains a key challenge. Operating cash flow has hovered around breakeven or slightly negative in most years, and free cash flow has followed the same pattern, since capital spending is relatively light. This means the business is not yet consistently funding itself from the cash it generates, and still depends on careful cost control, working capital management, and prior financing. Until the core MedTech platforms scale further, cash flow is likely to remain an important watch-point for overall financial health.

Competitive Edge

Competitive Edge Competitively, AngioDynamics is a focused specialist rather than a broad giant. Its strength lies in differentiated platforms like NanoKnife, Auryon, and its thrombectomy systems, which target specific, high-need procedures where outcomes and safety matter more than price alone. Strong intellectual property, physician relationships, and recurring revenue from disposables support its position. The flip side is that the company competes against much larger device makers with deeper pockets, and its success depends on continuing to win share in narrow but fast-growing niches rather than across the whole medical device market.

Innovation and R&D

Innovation and R&D Innovation is at the center of AngioDynamics’ strategy. The company has bet heavily on minimally invasive technologies, such as its irreversible electroporation system for tumor treatment, advanced atherectomy for peripheral artery disease, and mechanical thrombectomy for clot removal. These platforms require ongoing clinical trials, regulatory work, and product upgrades, which keep R&D spending high but can deepen the moat if successful. Future value will hinge on expanding approved uses, generating strong clinical data, and rolling out next-generation versions that are easier, safer, and more effective for physicians to adopt.

Summary

Overall, AngioDynamics looks like a clinically innovative, niche MedTech player that is still in financial transition. It has cleared debt, sharpened its focus on higher-growth, higher-margin technologies, and built a portfolio with clear medical differentiation. At the same time, it remains loss-making, with inconsistent cash flow and a smaller balance sheet than in prior years. The key tension is between strong technology and weak profitability: future outcomes will depend on how effectively the company converts its innovation and clinical momentum into durable revenue growth, operating leverage, and more reliable cash generation, all while navigating regulatory, competitive, and execution risks.

NEWS

October 27, 2025 · 4:30 PM UTC

AngioDynamics to Participate in the UBS Global Healthcare Conference

Read more

October 13, 2025 · 8:30 AM UTC

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

Read more

October 2, 2025 · 6:00 AM UTC

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Read more

September 18, 2025 · 8:00 AM UTC

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

Read more